Open heart · 2025
Assessment of β-blocker use and all-cause mortality in patients with myocardial infarction: a real-world analysis of the NHANES 1999-2018 database.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Ling Wang, Li Hongde, Liu Li, Sun Yansun, Qu Yannv
Аннотация
OBJECTIVE: To evaluate the association between β-blocker use and all-cause mortality in a real-world cohort of patients with myocardial infarction (MI).
METHODS: This study included 2308 patients with MI from the National Health and Nutrition Examination Survey (NHANES) 1999-2018. The primary outcome was all-cause mortality. Multiple approaches were employed to control for confounding, including multivariable Cox regression, propensity score matching and inverse probability of treatment weighting.
RESULTS: Based on data from 2308 patients with MI in the NHANES 1999-2018, with a mean follow-up of 84.6 months, this study evaluated the association between β-blocker use and all-cause mortality. The unadjusted analysis showed a significant protective effect (HR 0.81, 95% CI 0.68 to 0.96, p=0.0178). However, after multivariable adjustment for demographic, clinical and socioeconomic factors, as well as propensity score-based methods and inverse probability of treatment weighting, no significant association was observed (e.g., adjusted HR 1.04, 95% CI 0.87 to 1.25, p=0.6733). Stratified analyses did not reveal significant effect modification by any covariate (all p interaction value >0.05).
CONCLUSION: After adjustment for measured confounders, this analysis found no significant association between β-blocker use and all-cause mortality in this real-world MI cohort.
METHODS: This study included 2308 patients with MI from the National Health and Nutrition Examination Survey (NHANES) 1999-2018. The primary outcome was all-cause mortality. Multiple approaches were employed to control for confounding, including multivariable Cox regression, propensity score matching and inverse probability of treatment weighting.
RESULTS: Based on data from 2308 patients with MI in the NHANES 1999-2018, with a mean follow-up of 84.6 months, this study evaluated the association between β-blocker use and all-cause mortality. The unadjusted analysis showed a significant protective effect (HR 0.81, 95% CI 0.68 to 0.96, p=0.0178). However, after multivariable adjustment for demographic, clinical and socioeconomic factors, as well as propensity score-based methods and inverse probability of treatment weighting, no significant association was observed (e.g., adjusted HR 1.04, 95% CI 0.87 to 1.25, p=0.6733). Stratified analyses did not reveal significant effect modification by any covariate (all p interaction value >0.05).
CONCLUSION: After adjustment for measured confounders, this analysis found no significant association between β-blocker use and all-cause mortality in this real-world MI cohort.